Actavis Agrees To Hold Off On Generic Nuvigil

Law360, New York (March 22, 2011, 5:55 PM EDT) -- Cephalon Inc. on Tuesday dropped a patent infringement suit in Delaware against Actavis Inc. following the generic-drug maker’s decision not to market a competing version of narcolepsy drug Nuvigil.

Judge Gregory Sleet of the U.S. District Court for the District of Delaware closed Cephalon’s case against Actavis after Actavis agreed to hold off from introducing its proposed generic Nuvigil product until the expiration of the asserted patent.

Cephalon filed suit against Actavis in December 2009, claiming the company infringed U.S. Patent Number 7,132,570 when seeking regulatory...
To view the full article, register now.